273 related articles for article (PubMed ID: 38551031)
1. Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
Flaherty RL; Sflomos G; Brisken C
Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38551031
[TBL] [Abstract][Full Text] [Related]
2. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Coates RJ; Marchbanks PA; Norman SA; Weiss LK; Ursin G; Berlin JA; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Wingo PA; Spirtas R
Cancer; 2002 Dec; 95(12):2455-64. PubMed ID: 12467057
[TBL] [Abstract][Full Text] [Related]
3. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.
Rosenberg LU; Magnusson C; Lindström E; Wedrén S; Hall P; Dickman PW
Breast Cancer Res; 2006; 8(1):R11. PubMed ID: 16507159
[TBL] [Abstract][Full Text] [Related]
5. Menopausal hormone therapy and risk of clinical breast cancer subtypes.
Slanger TE; Chang-Claude JC; Obi N; Kropp S; Berger J; Vettorazzi E; Braendle W; Bastert G; Hentschel S; Flesch-Janys D
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1188-96. PubMed ID: 19336542
[TBL] [Abstract][Full Text] [Related]
6. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype.
Calle EE; Feigelson HS; Hildebrand JS; Teras LR; Thun MJ; Rodriguez C
Cancer; 2009 Mar; 115(5):936-45. PubMed ID: 19156895
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.
Li CI; Weiss NS; Stanford JL; Daling JR
Cancer; 2000 Jun; 88(11):2570-7. PubMed ID: 10861435
[TBL] [Abstract][Full Text] [Related]
9. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.
Li CI; Malone KE; Porter PL; Lawton TJ; Voigt LF; Cushing-Haugen KL; Lin MG; Yuan X; Daling JR
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):43-50. PubMed ID: 18199710
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.
Reeves GK; Beral V; Green J; Gathani T; Bull D;
Lancet Oncol; 2006 Nov; 7(11):910-8. PubMed ID: 17081916
[TBL] [Abstract][Full Text] [Related]
11. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
Li CI; Daling JR; Haugen KL; Tang MT; Porter PL; Malone KE
Breast Cancer Res Treat; 2014 Jun; 145(2):481-9. PubMed ID: 24748570
[TBL] [Abstract][Full Text] [Related]
12. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
13. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study.
Li CI; Chlebowski RT; Freiberg M; Johnson KC; Kuller L; Lane D; Lessin L; O'Sullivan MJ; Wactawski-Wende J; Yasmeen S; Prentice R
J Natl Cancer Inst; 2010 Sep; 102(18):1422-31. PubMed ID: 20733117
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States).
Newcomer LM; Newcomb PA; Potter JD; Yasui Y; Trentham-Dietz A; Storer BE; Longnecker MP; Baron JA; Daling JR
Cancer Causes Control; 2003 Apr; 14(3):225-33. PubMed ID: 12814201
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population.
Phipps AI; Li CI; Kerlikowske K; Barlow WE; Buist DS
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1643-54. PubMed ID: 20501751
[TBL] [Abstract][Full Text] [Related]
16. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.
Pike MC; Spicer DV; Dahmoush L; Press MF
Epidemiol Rev; 1993; 15(1):17-35. PubMed ID: 8405201
[TBL] [Abstract][Full Text] [Related]
17. Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Dossus L; Benusiglio PR
Breast Cancer Res; 2015 Mar; 17():37. PubMed ID: 25848941
[TBL] [Abstract][Full Text] [Related]
18. Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
King RJ
Contraception; 1991 Jun; 43(6):527-42. PubMed ID: 1651204
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
20. Sex steroids and breast cancer prevention.
Spicer DV; Pike MC
J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
